Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02436733
Other study ID # EORTC-1205
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 20, 2016
Est. completion date September 2023

Study information

Verified date November 2022
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage MPM will be randomized between Arm A: immediate P/D followed by three cycles of chemotherapy (pemetrexed 500mg/m2 and cisplatin 75 mg/m2, both drugs given on day 1, every three weeks) Arm B: three cycles of chemotherapy (same regimen) followed by P/D, for non-progressing patients


Description:

This is an academic led, multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage MPM will be randomized between - Arm A - immediate surgery: immediate P/D followed by three cycles of chemotherapy (pemetrexed 500mg/m2 and cisplatin 75 mg/m2, both drugs given on day 1, every three weeks) for non-progressing patients - Arm B - delayed surgery: three cycles of chemotherapy (same regimen) followed by P/D, for non-progressing patients. A maximum of four weeks (±2 weeks) will be allowed between the baseline tumor assessment and the start of treatment (surgery or chemotherapy). Randomization should be done as soon as possible after baseline tumor assessment. The primary objective of the study is to investigate the feasibility of immediate P/D followed by cisplatin/pemetrexed chemotherapy or deferred P/D after cisplatin/pemetrexed chemotherapy in patients with early stage MPM. The results of this study will allow the LCG to take one of the arms further to a comparative study with either no surgery or EPP as control arm. The choice of the comparator will depend on the result of a parallel ongoing randomized study in the UK, comparing P/D with no surgery


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 64
Est. completion date September 2023
Est. primary completion date July 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Patients aged 18 years or older, with pathologically proven malignant pleural mesothelioma. All histological subtypes are accepted. - Stage cT1-3, N0-2, M0 according to UICC TNM classification. FDG-PET-CT scan showing absence of M1, N3, supraclavicular and coeliac node involvement is required. No clinical invasion of mediastinal structures (heart, aorta, spine, esophagus, etc.) and no widespread chest wall invasion (T4) are acceptable. Focal chest wall lesions are acceptable. - No prior treatment of any kind for mesothelioma is allowed, especially prophylactic track irradiation after diagnostic procedures. - WHO performance status 0-1 - Fit to receive chemotherapy and undergo a pleurectomy/ decortication with optional removal of hemidiaphragm and pericardium. - No history of other malignancy within the last three years, except for carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin. - No pre-existing peripheral sensory or motor neuropathy > grade I according to CTCAE v4.0 - No clinically significant pleural effusion that cannot be managed with thoracentesis or pleurodesis (according to institutional practice). If pleurodesis is considered, it should be done before randomization. - Adequate organ function Women of child bearing potential must have a negative serum (or urine) pregnancy test within 3 days prior to the start of chemotherapy/surgery. Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least three months after the last study treatment. Before patient registration written informed consent must be given according to ICH/GCP, and national/local regulations. Exclusion Criteria • Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures, known infection with HIV, active hepatitis B and/or hepatitis C virus). significant cardiovascular morbidity (assessed by cardiologist) precluding surgery - Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery (other than P/D) during the course of study treatment. - History of receiving any investigational treatment within 28 days of randomization. - History of intolerance to pemetrexed and/or cisplatin. - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol.

Study Design


Intervention

Procedure:
pleurectomy/decortication
Lung sparing procedures consist of the resection of the pleura without removing the lung
Drug:
Pemetrexed/Cisplatin
On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.

Locations

Country Name City State
Belgium UZ Antwerpen Antwerpen
Belgium UZ Gent Gent
Netherlands The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis Amsterdam
Netherlands Erasmus MC Hospital Rotterdam

Sponsors (1)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC

Countries where clinical trial is conducted

Belgium,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of success to complete the full treatment A patient is considered to be a "treatment success" if he/she meets all of the following criteria:
Patient has received the full protocol treatment, defined as 3 cycles of pemetrexed and cisplatin (allowing for the dose adjustments described in section 5.3), preceded/followed by pleurectomy/decortication (P/D) (as described in section 5.3).
Patient alive and has no evidence of progression/relapse at week 20 (±2 weeks) after the first day of starting protocol treatment (either chemotherapy or P/D).
Patient has no persisting grade 3-4 treatment side-effects (CTCAE V 4.0) at week 20 (±2 weeks) after the first day of starting protocol treatment (either chemotherapy or P/D)
20weeks
Secondary Loco-regional failure free survival Loco-Regional Failure Free Survival (LRFFS) is defined as the time interval between the date of randomization and the date of relapse in hemithorax or mediastinum or death, whichever comes first 6 months
Secondary Overall survival the time interval between the date of randomization and the date of death of any cause 15 months
Secondary Treatment side-effects Treatment side-effects will be assessed for all patients and graded per CTCAE category upon occurrence of the event. The investigator will assess whether those events are surgery or/and drug related (no reasonable possibility, reasonable possibility) and this assessment will be recorded in the database for all adverse events. Surgical side effects during the perioperative period will be scored according to the Clavien-Dindo Classification of Surgical Complications as an exploratory approach. 36 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06037941 - Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma N/A
Completed NCT01675765 - Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma Phase 1
Withdrawn NCT04201145 - Pembrolizumab + Defactinib In Pleural Mesothelioma Phase 1
Completed NCT03048474 - Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma Phase 2
Completed NCT02369198 - MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC Phase 1
Terminated NCT01870609 - Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT00886028 - Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Phase 2
Completed NCT00272558 - Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma Phase 2
Completed NCT04843007 - Alvopem® (Pemetrexed) Safety Assessment
Completed NCT01721018 - Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Phase 1/Phase 2
Active, not recruiting NCT00797719 - Short Neoadjuvant Hemithoracic IMRT for MPM Phase 1/Phase 2
Completed NCT00386815 - Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Phase 2
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Completed NCT04775446 - Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Completed NCT01644994 - Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma Phase 1/Phase 2
Completed NCT01865045 - Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
Completed NCT00571298 - Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma Phase 1
Recruiting NCT01343264 - Trimodality Therapy for Malignant Pleural Mesothelioma N/A
Active, not recruiting NCT04162015 - A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma Phase 1
Recruiting NCT04400539 - The IMmunotherapy Pleural 5-ALA PDT Phase 2